Compounds > methamphetamine

methamphetamine and lisdexamfetamine dimesylate

methamphetamine has been researched along with lisdexamfetamine dimesylate in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Bissaker, A; Bruno, R; Carr, A; Clifford, B; Dunlop, A; Ezard, N; Lintzeris, N1
Ali, R; Baker, AL; Bruno, R; Carr, A; Clifford, B; Dolan, K; Dunlop, A; Ezard, N; Hall, M; Lintzeris, N; Liu, Z; McKetin, R; Phung, N; Shanahan, M; White, J1
Bruno, R; Carr, A; Clifford, B; Dunlop, A; Ezard, N; Lintzeris, N; Liu, Z; Siefried, KJ1
Acheson, LS; Brett, J; Christmass, M; Dunlop, A; Ezard, N; Farrell, M; Gill, A; Lintzeris, N; McKetin, R; Rodgers, C; Shoptaw, S; Siefried, KJ2

Trials

5 trial(s) available for methamphetamine and lisdexamfetamine dimesylate

ArticleYear
Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence.
    BMC psychiatry, 2016, Dec-01, Volume: 16, Issue:1

    Topics: Adult; Amphetamine-Related Disorders; Australia; Central Nervous System Stimulants; Counseling; Dose-Response Relationship, Drug; Female; Humans; Lisdexamfetamine Dimesylate; Male; Methamphetamine; Single-Blind Method; Treatment Outcome

2016
LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence.
    BMJ open, 2018, 07-19, Volume: 8, Issue:7

    Topics: Amphetamine-Related Disorders; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Cost-Benefit Analysis; Double-Blind Method; Humans; Lisdexamfetamine Dimesylate; Methamphetamine; Randomized Controlled Trials as Topic; Self Report; Substance Abuse Detection; Urinalysis

2018
Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study.
    BMJ open, 2021, 05-18, Volume: 11, Issue:5

    Topics: Adolescent; Adult; Amphetamine-Related Disorders; Australia; Central Nervous System Stimulants; Double-Blind Method; Humans; Lisdexamfetamine Dimesylate; Methamphetamine; Treatment Outcome

2021
Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal.
    PloS one, 2022, Volume: 17, Issue:10

    Topics: Alcoholism; Amphetamine-Related Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Double-Blind Method; Humans; Lisdexamfetamine Dimesylate; Methamphetamine; Pilot Projects; Substance Withdrawal Syndrome; Treatment Outcome

2022
Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Adult; Alcoholism; Amphetamine-Related Disorders; Central Nervous System Stimulants; Humans; Lisdexamfetamine Dimesylate; Male; Methamphetamine; Pilot Projects; Substance Withdrawal Syndrome; Treatment Outcome

2022